BioRestorative Therapies (BRTX) Operating Income (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Operating Income came in at -$3.8 million in Q4 2025, down 42.2% YoY from -$6.6 million in Q4 2024, and down 3.14% on a QoQ basis from -$3.7 million in Q3 2025.
BioRestorative Therapies (BRTX) Operating Income (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Operating Income data on file, last reported at -$3.8 million in Q4 2025.
- Quarterly Operating Income fell 42.2% year-over-year to -$3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.6 million (down 35.41% YoY) and the FY2025 annual result came in at -$15.6 million, down 35.41% from the prior year.
- Operating Income slipped to -$3.8 million in Q4 2025, from -$3.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.3 million in Q3 2024 to a low of -$15.1 million in Q1 2021.
- A 5-year average of -$4.4 million and a median of -$3.8 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income sank 1738.2% — and 2022, when it surged 66.43%.
- Tracing BRTX's Operating Income over 5 years: stood at -$4.0 million in 2021, then slipped by 16.78% to -$4.7 million in 2022, then surged by 31.21% to -$3.2 million in 2023, then climbed by 16.47% to -$2.7 million in 2024, then tumbled by 42.2% to -$3.8 million in 2025.
- The last three Operating Income figures came in at -$3.8 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | BioRestorative Therapies | 1.97 Mn | -983,429.84 | 17,964.00 | -3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.83 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | -3.31 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Dec 31, 2024 | -2.69 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.47 Mn |
| Mar 31, 2024 | -4.11 Mn |
| Dec 31, 2023 | -3.22 Mn |
| Sep 30, 2023 | -3.10 Mn |
| Jun 30, 2023 | -3.12 Mn |
| Mar 31, 2023 | -5.78 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -4.61 Mn |
| Jun 30, 2022 | -4.63 Mn |
| Mar 31, 2022 | -5.05 Mn |
| Dec 31, 2021 | -4.01 Mn |
| Sep 30, 2021 | -3.69 Mn |
| Jun 30, 2021 | -3.56 Mn |
| Mar 31, 2021 | -15.05 Mn |